PURPOSE: Stereotactic radiosurgery (SRS) is well accepted treatment for patients with intracranial metastases, but the role of frameless radiosurgery is not well defined. Here, we describe our clinical experience applying a novel single-isocenter technique to frameless intensity modulated stereotactic radiosurgery (IMRS) for simultaneous treatment of multiple intracranial metastases. METHODS AND MATERIALS: Between 2006 and 2012, 100 consecutive patients received frameless IMRS for multiple intracranial metastases using a single, centrally-located isocenter. Among these, 29 patients were treated for progressive or recurrent intracranial disease. A total of 465 metastases (median, 4 per patient, range, 2-18) were treated to a median dose of 20 Gy (range, 15-50 Gy). Follow-up including clinical examination and magnetic resonance imaging (MRI) occurred every 3 months. RESULTS: Median follow-up for all patients was 4.3 months (range, 0.2-58.3 months), with 83 patients (83.0%) followed until their death. For the remaining 17 patients alive at the time of analysis, median follow-up was 9.2 months (range, 2.2-58.3 months). Overall survival at 6 months was 49.5% [95% confidence interval (CI), 35.3-63.6%]. Local control at 6 and 12 months was 88.9% (95% CI, 79.1-98.6%) and 81.5% (95% CI, 65.2-97.7%), respectively. Regional failure was observed in 39 patients (39%), and 25 patients (25%) received salvage therapy. Grade 3 or greater treatment-related toxicity was observed in 4 patients (4%) and included intracranial hemorrhage, seizure, and radionecrosis. Median total treatment time was 17.2 minutes (range, 2.8-55.3 minutes). CONCLUSIONS: Single-isocenter IMRS for multiple intracranial metastases can produce clinical outcomes comparable to those of conventional radiosurgery techniques.
PURPOSE: Stereotactic radiosurgery (SRS) is well accepted treatment for patients with intracranial metastases, but the role of frameless radiosurgery is not well defined. Here, we describe our clinical experience applying a novel single-isocenter technique to frameless intensity modulated stereotactic radiosurgery (IMRS) for simultaneous treatment of multiple intracranial metastases. METHODS AND MATERIALS: Between 2006 and 2012, 100 consecutive patients received frameless IMRS for multiple intracranial metastases using a single, centrally-located isocenter. Among these, 29 patients were treated for progressive or recurrent intracranial disease. A total of 465 metastases (median, 4 per patient, range, 2-18) were treated to a median dose of 20 Gy (range, 15-50 Gy). Follow-up including clinical examination and magnetic resonance imaging (MRI) occurred every 3 months. RESULTS: Median follow-up for all patients was 4.3 months (range, 0.2-58.3 months), with 83 patients (83.0%) followed until their death. For the remaining 17 patients alive at the time of analysis, median follow-up was 9.2 months (range, 2.2-58.3 months). Overall survival at 6 months was 49.5% [95% confidence interval (CI), 35.3-63.6%]. Local control at 6 and 12 months was 88.9% (95% CI, 79.1-98.6%) and 81.5% (95% CI, 65.2-97.7%), respectively. Regional failure was observed in 39 patients (39%), and 25 patients (25%) received salvage therapy. Grade 3 or greater treatment-related toxicity was observed in 4 patients (4%) and included intracranial hemorrhage, seizure, and radionecrosis. Median total treatment time was 17.2 minutes (range, 2.8-55.3 minutes). CONCLUSIONS: Single-isocenter IMRS for multiple intracranial metastases can produce clinical outcomes comparable to those of conventional radiosurgery techniques.
Authors: Reena Kamath; Timothy C Ryken; Sanford L Meeks; Edward C Pennington; Justine Ritchie; John M Buatti Journal: Int J Radiat Oncol Biol Phys Date: 2005-04-01 Impact factor: 7.038
Authors: Imjai Chitapanarux; Bryan Goss; Roy Vongtama; Leonardo Frighetto; Antonio De Salles; Michael Selch; Michael Duick; Timothy Solberg; Robert Wallace; Cynthia Cabatan-Awang; Judith Ford Journal: J Neurooncol Date: 2003-01 Impact factor: 4.130
Authors: Laura I Cerviño; Nicole Detorie; Matthew Taylor; Joshua D Lawson; Taylor Harry; Kevin T Murphy; Arno J Mundt; Steve B Jiang; Todd A Pawlicki Journal: Pract Radiat Oncol Date: 2011-12-20
Authors: Jean L Peng; Darren Kahler; Jonathan G Li; Sanjiv Samant; Guanghua Yan; Robert Amdur; Chihray Liu Journal: Med Phys Date: 2010-10 Impact factor: 4.071
Authors: Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers Journal: Lancet Oncol Date: 2009-10-02 Impact factor: 41.316
Authors: Steven K M Lau; Kaveh Zakeri; Xiao Zhao; Ruben Carmona; Erik Knipprath; Daniel R Simpson; Sameer K Nath; Gwe-Ya Kim; Parag Sanghvi; Jona A Hattangadi-Gluth; Clark C Chen; Kevin T Murphy Journal: Neurosurgery Date: 2015-08 Impact factor: 4.654
Authors: Steven K M Lau; Kunal Patel; Teddy Kim; Erik Knipprath; Gwe-Ya Kim; Laura I Cerviño; Joshua D Lawson; Kevin T Murphy; Parag Sanghvi; Bob S Carter; Clark C Chen Journal: J Neurooncol Date: 2017-01-24 Impact factor: 4.130
Authors: Jasmine A Oliver; Omar A Zeidan; Sanford L Meeks; Amish P Shah; Jason Pukala; Patrick Kelly; Naren R Ramakrishna; Twyla R Willoughby Journal: J Appl Clin Med Phys Date: 2017-04-24 Impact factor: 2.102